Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.51 USD
+0.21 (0.29%)
Updated Jul 18, 2024 04:00 PM ET
After-Market: $73.37 -0.14 (-0.19%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.51 USD
+0.21 (0.29%)
Updated Jul 18, 2024 04:00 PM ET
After-Market: $73.37 -0.14 (-0.19%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights: Ford, Pinterest, Peloton Interactive, Gilead Sciences and T-Mobile US
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Ford, Pinterest, Peloton Interactive, Gilead Sciences and T-Mobile US
Massive Q4 Earnings Beats: Ford, Pinterest, Peloton & More
by Mark Vickery
There are so many companies hitting the tape with earnings reports in the after-hours, we only have time to touch on a few of them.
Gilead Sciences (GILD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 1.86% and 4.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Ligand (LGND) Q4 Earnings & Sales Top, 2021 Guidance Raised
by Zacks Equity Research
Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.
Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody
by Zacks Equity Research
Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.
Will Eylea, Dupixent Drive Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports fourth-quarter 2020 results.
SAP SE (SAP) Q4 Earnings and Revenues Decline Y/Y, Stock Down
by Zacks Equity Research
SAP SE (SAP) fourth-quarter results reflect lingering coronavirus crisis led business impacts on Concur solutions. However, gain from high demand for digital supply chain, Qualtrics and cloud platform solutions supported the top line.
Will Strong Veklury Sales Aid Gilead's (GILD) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports fourth-quarter 2020 results.
Eli Lilly (LLY) Q4 Earnings Top, COVID-19 Antibody Boosts Sales
by Zacks Equity Research
Lilly (LLY) beats fourth-quarter estimates for both earnings and sales. Stock up in pre-market trading.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $64.68, marking a -1.22% move from the previous day.
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.
What's in the Cards for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the fourth quarter is what remains to be seen when the company reports results.
Will Trikafta Drive Vertex's (VRTX) Revenues in Q4 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta.
Lilly's (LLY) Bamlanivimab Combo Lowers COVID-19 Hospitalization
by Zacks Equity Research
Eli Lilly's (LLY) combination of its COVID-19 antibodies bamlanivimab (LY-CoV555) plus etesevimab (LY-CoV016) reduces COVID-19-related hospitalizations and deaths by 70%.
Will Eli Lilly (LLY) Beat Estimates This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.
Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes
by Zacks Equity Research
Eli Lilly's (LLY) COVID-19 antibody drug bamlanivimab (LY-CoV555) reduces risk of contracting symptomatic COVID-19 infection by 80% at nursing homes in the United States.
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.
Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar
by Zacks Equity Research
Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.
Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod
by Zacks Equity Research
The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.
What's in Store for UnitedHealth (UNH) This Earnings Season?
by Zacks Equity Research
UnitedHealth's (UNH) earnings results are likely to reflect solid contribution from its segments, namely Healthcare and Optum, partly offset by higher claim costs.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $63.33 in the latest trading session, marking a +1.49% move from the prior day.
Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY
by Zacks Equity Research
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.